nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-3196Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESДислипидемии у больных с терминальной уремией на постоянном амбулаторном перитонеальном диализе (ПАПД)Lipid abnormalities in patients on continuous ambulatory peritoneal dialysisЕрмоленкоВ. М.ErmolenkoV. M.noemail@neicon.ruЯроваяГ. А.YarovayaG. A.noemail@neicon.ruШутовЕ. В.ShutovE. V.noemail@neicon.ruГрабскаяЕ. С.GrabskayaE. S.noemail@neicon.ruКафедра нефрологии и гемодиализа, кафедра биохимии Российской медицинской академии последипломного образования МЗ РФ; Московская городская больница им. С.П. БоткинаRussian Federation20022806202542118120Copyright © Ермоленко В.М., Яровая Г.А., Шутов Е.В., Грабская Е.С., 20252025Ермоленко В.М., Яровая Г.А., Шутов Е.В., Грабская Е.С.Ermolenko V.M., Yarovaya G.A., Shutov E.V., Grabskaya E.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/3196

В течение 2 лет изучали содержание липидов и липопротеинов у 46 пациентов, находящихся на постоянном амбулаторном перитонеальном диализе. Определялся ОХ, ТГ, ЛВП, ЛОНП, ЛНП, апопротеины А-1 и В. В процессе лечения ПАПД у больных прогрессивно ухудшался липидный профиль сыворотки крови. С целью коррекции дислипидемий 20 пациентам назначили гиполипидемическую терапию. 10 больных с высоким уровнем ОХ получали 5 мг симвастатина в сутки в течение 6 месяцев. 10 пациентов с высоким уровнем ТГ лечили ципрофибратом - 50 мг в сутки в течение 6 мес. В результате проведенной терапии произошли позитивные сдвиги в липидном спектре сыворотки крови, что позволяет рекомендовать эти препараты для использования у пациентов с терминальной уремией на ПАПД.

During 2 years the effects of continuous ambulatory peritoneal dialysis (CAPD) on serum lipids and lipoproteins in 46 uremic patients were studied. The concentrations of very low density lipoproteins (VLDL) cholesterol (CHOL), LDL CHOL, serum CHOL and serum triglycerides (TG) increased significantly. High density lipoprotein CHOL have been reduced. We examined the effects of simvastatin, an HMG-CoA reductase inhibitor, and lipanor (ciprofibrat) on lipoprotein parameters in 20 uremic patients treated with CAPD. The patients with elevated cholesterol (n = 10) were administrated with 5 mg/day simvastatin for 6 months, the patients with elevated triglycerids obtained lipanor 50 mg/day. Significant decrease in serum total lipid, TG, and CHOL levels were observed when compared to pretreatment values. Our results confirm the adverse effect of CAPD on serum lipids. We conclude that simvastatin and ciprofibrat effective to the management of dyslipidemia in uremic patients treated with CAPD.

дислипидемиялипопротеиныПАПДуремияReferencesТитов В.Н. Аполипопротеин (а) как тест активности атеросклероза. Клиническая лабораторная диагностика 1997: 11.Титов В.Н. Аполипопротеин (а) как тест активности атеросклероза. Клиническая лабораторная диагностика 1997: 11.Avram M., Fein P., Antingani A. et al. Cholesterol and lipid disturbances in renal disease: The natural history of uremic dislipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. Am. J. Med. 1989; 87; Suppl. 5: 5-55.Avram M., Fein P., Antingani A. et al. Cholesterol and lipid disturbances in renal disease: The natural history of uremic dislipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. Am. J. Med. 1989; 87; Suppl. 5: 5-55.Chan M., Varghese Z., Persaud J. et al. Hyperlipidemia in patients on maintenance hemo- and peritoneal dialysis: The relative pathogenetic roles of triglyceride production and triglyceride removal. Clin. Nephrol. 1982; 17: 183-190.Chan M., Varghese Z., Persaud J. et al. Hyperlipidemia in patients on maintenance hemo- and peritoneal dialysis: The relative pathogenetic roles of triglyceride production and triglyceride removal. Clin. Nephrol. 1982; 17: 183-190.Chan M.K., Varghese Z., Moorhead I.F. Lipid abnormalities in uremia, dialysis and transplantation Kidney Int. 1981; 19; 5: 625-637.Chan M.K., Varghese Z., Moorhead I.F. Lipid abnormalities in uremia, dialysis and transplantation Kidney Int. 1981; 19; 5: 625-637.Friedewald W., Levvy R., Fredrickson D. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugation. Clin. Chem. 1972; 18: 499-502.Friedewald W., Levvy R., Fredrickson D. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugation. Clin. Chem. 1972; 18: 499-502.Kagan A., Bar-Khayim Y., Schaefer Z., Fainaru M. Kinetics of peritoneal protein loss during CAPD: lipoprotein leakage and its impact on plasma lipid levels. Kidney Int. 1990; 37: 980-990.Kagan A., Bar-Khayim Y., Schaefer Z., Fainaru M. Kinetics of peritoneal protein loss during CAPD: lipoprotein leakage and its impact on plasma lipid levels. Kidney Int. 1990; 37: 980-990.Kawaguchi Y., Kubo H., Yamamoto H. et al. Is atherosclerosis accelerated by CAPD. Am. Heart. J. 1990; 119: 334-352.Kawaguchi Y., Kubo H., Yamamoto H. et al. Is atherosclerosis accelerated by CAPD. Am. Heart. J. 1990; 119: 334-352.Lindholm B., Norbeck H. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med. Scand. 1986; 220: 143-151.Lindholm B., Norbeck H. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med. Scand. 1986; 220: 143-151.Llopard R., Donate T., Oliva J. et al. Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients. Nephrol. Dial. Transplant. 1995; 10: 537-540.Llopard R., Donate T., Oliva J. et al. Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients. Nephrol. Dial. Transplant. 1995; 10: 537-540.Nishizawa Y., Shoji T., Emoto M. et al. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients. Clin. Nephrol. 1995; 43; 4: 268-277.Nishizawa Y., Shoji T., Emoto M. et al. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients. Clin. Nephrol. 1995; 43; 4: 268-277.O’Neal D., Lee P., Murthy B., Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am. J. Kidney. Dis. 1996; 27 (1): 84-91.O’Neal D., Lee P., Murthy B., Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am. J. Kidney. Dis. 1996; 27 (1): 84-91.Sander J. Robins. Management of Lipid Disordes: A Basic and Guide for Therapeutic Intervenshion. Перевод с англ. В.А. Метельской. М.: Медицина, 2001: 87-109.Sander J. Robins. Management of Lipid Disordes: A Basic and Guide for Therapeutic Intervenshion. Перевод с англ. В.А. Метельской. М.: Медицина, 2001: 87-109.

The authors declare that there are no conflicts of interest present.